We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Catalyst Biosciences Inc | NASDAQ:CBIO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.5113 | 0.53 | 0.5796 | 0 | 01:00:00 |
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Item 7.01. |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit Number
|
Exhibit Title or Description
|
|
Press Release, dated December 6, 2023
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
GYRE THERAPEUTICS, INC.
|
||
Date: December 6, 2023
|
By:
|
/s/ Charles C. Wu, Ph.D.
|
Name:
|
Charles C. Wu, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Company Name:
|
GNI Group Ltd.
|
|
Representative:
|
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
|
|
(Security Code: 2160, TSE Growth)
|
||
Contact Person:
|
Chief Financial Officer
Toshiya Kitagawa
|
|
(TEL. 03-6214-3600)
|
1) |
Update of Other Income
|
2) |
Update of Forecast
|
1. |
The differences between the previous and the updated 2023 consolidated
earnings forecast for full-year 2023 (January 1, 2023 – December 31, 2023)
|
|
Revenue
|
|
Operating
profit
|
|
Profit before
tax
|
|
Profit for
the year
|
|
Profit
attributable to
owners of the
parent
|
|
Basic earnings
per share
|
||
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY)
|
||
|
Previous Forecast (A)
|
|
26,267
|
|
7,280
|
|
6,430
|
|
4,351
|
|
2,005
|
|
42.20
|
|
Revised Forecast (B)
|
|
26,300
|
|
15,744
|
|
14,865
|
|
11,234
|
|
8,971
|
|
180.42
|
|
Difference (B-A)
|
|
33
|
|
8,464
|
|
8,435
|
|
6,883
|
|
6,966
|
|
-
|
|
Difference in ratio (%)
|
|
0.1%
|
|
116.3%
|
|
131.2%
|
|
158.2%
|
|
347.4%
|
|
-
|
|
(Reference) 2022 Actual
|
|
17,418
|
|
1,377
|
|
767
|
|
(868)
|
|
388
|
|
8.19
|
2. |
Reasons for the differences
|
Document and Entity Information |
Dec. 06, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 06, 2023 |
Entity File Number | 000-51173 |
Entity Registrant Name | Gyre Therapeutics, Inc. |
Entity Central Index Key | 0001124105 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2020050 |
Entity Address, Address Line One | 12770 High Bluff Drive |
Entity Address, Address Line Two | Suite 150 |
Entity Address, City or Town | San Diego, |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | 619 |
Local Phone Number | 949-3681 |
Title of 12(b) Security | Common Stock |
Trading Symbol | GYRE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
1 Year Catalyst Biosciences Chart |
1 Month Catalyst Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions